首页> 外文期刊>ACS medicinal chemistry letters >Discovery of 5-Amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Inhibitors of IRAK4
【24h】

Discovery of 5-Amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Inhibitors of IRAK4

机译:IRAK4的5-氨基-N-(1H-吡唑-4-基)吡唑并[1,5-a]嘧啶-3-甲酰胺抑制剂的发现

获取原文
获取原文并翻译 | 示例
           

摘要

Interleukin-1 receptor associated kinase 4 (IRAK4) is an essential signal transducer downstream of the IL-1R and TLR superfamily, and selective inhibition of the kinase activity of the protein represents an attractive target for the treatment of inflammatory diseases. A series of 5-amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamides was developed via sequential modifications to the 5-position of the pyrazolopyrimidine ring and the 3-position of the pyrazole ring. Replacement of substituents responsible for poor permeability and improvement of physical properties guided by cLogD led to the identification of IRAK4 inhibitors with excellent potency, kinase selectivity, and pharmacokinetic properties suitable for oral dosing.
机译:白介素-1受体相关激酶4(IRAK4)是IL-1R和TLR超家族下游的重要信号转导子,对蛋白激酶活性的选择性抑制代表了炎性疾病的治疗目标。通过对吡唑并嘧啶环的5-位和3-位进行顺序修饰,开发了一系列5-氨基-N-(1H-吡唑-4-基)吡唑并[1,5-a]嘧啶-3-羧酰胺吡唑环。由cLogD指导的取代物造成的渗透性差和物理性质改善,导致了IRAK4抑制剂的鉴定,该抑制剂具有出色的效力,激酶选择性和适合口服给药的药代动力学特性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号